Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome

Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome....

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroimmunology Vol. 346; p. 577308
Main Authors Garcia-Estrada, Christian, Casallas-Vanegas, Adriana, Zabala-Angeles, Indhira, Gomez-Figueroa, Enrique, Rivas-Alonso, Verónica, Flores-Rivera, José
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 15.09.2020
Subjects
Myelitis
Neuro-Behçet
Pseudotumoral lesion
Rituximab
Pseudotumoral lesion
Rituximab
Myelitis
Neuro-Behçet
NB
Online AccessGet full text

Cover

More Information
Summary:Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome. Currently there are no treatment guidelines either for BS or NB, making the management of these patients particularly difficult. We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy. This is the first report of concomitant pseudo-tumoral lesion and myelitis secondary to BS. We found rituximab treatment to be a safe and effective therapeutic option for NB supported by the radiological and clinical improvement achieved in our patient. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2020.577308